Longeveron (NASDAQ:LGVN) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Longeveron (NASDAQ:LGVN) in a research report released on Friday morning,Benzinga reports. The firm currently has a $10.00 price objective on the stock.

LGVN has been the topic of several other reports. Roth Capital raised Longeveron to a “strong-buy” rating in a report on Thursday, December 5th. Roth Mkm started coverage on shares of Longeveron in a research note on Friday, December 6th. They issued a “buy” rating and a $10.00 price target on the stock.

Longeveron Stock Performance

LGVN stock opened at $1.85 on Friday. The firm has a market capitalization of $27.62 million, a price-to-earnings ratio of -0.29 and a beta of 0.37. The firm has a 50 day moving average price of $1.60 and a 200-day moving average price of $1.84. Longeveron has a 52-week low of $0.77 and a 52-week high of $6.40.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Geode Capital Management LLC raised its position in Longeveron by 316.0% in the 3rd quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock worth $250,000 after buying an additional 97,953 shares during the last quarter. Virtu Financial LLC bought a new position in Longeveron during the fourth quarter valued at approximately $53,000. Jane Street Group LLC purchased a new stake in Longeveron in the fourth quarter worth approximately $35,000. Northern Trust Corp bought a new stake in Longeveron in the 4th quarter worth approximately $31,000. Finally, State Street Corp purchased a new stake in Longeveron during the 3rd quarter valued at $29,000. Hedge funds and other institutional investors own 10.01% of the company’s stock.

About Longeveron

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.